Vectura Group PLC represents values and a corporate philosophy centered around innovation, integrity, and patient-centricity. As a leading provider of inhaled drug delivery solutions, Vectura strives to transform patient outcomes and improve quality of life through its advanced technologies and expertise in respiratory treatments. By focusing on innovation, Vectura continuously develops and collaborates on groundbreaking inhalation therapies, addressing unmet medical needs globally. With an unwavering commitment to integrity, the company conducts its business ethically and transparently, adhering to the highest industry standards. Through its patient-centric approach, Vectura aims to empower individuals by delivering effective, accessible, and personalized respiratory care solutions.

Vectura Group PLC is primarily present in various countries and regions across the globe. The company has a significant presence in the United Kingdom where it is headquartered. Additionally, Vectura has a strong presence in Europe, with operations and partnerships in several major European countries such as Germany, France, Italy, and Spain. Moreover, the company has expanded its reach to other regions including the United States, Canada, and Asia. With its diversified presence, Vectura Group PLC is well-positioned to serve and cater to a wide range of markets and customers around the world.

Vectura Group PLC, a reputable stock company, has accomplished several significant milestones. In its rich history, Vectura has consistently demonstrated excellence and achieved remarkable success. Notably, the company has successfully developed innovative respiratory therapies, establishing itself as a key player in the pharmaceutical industry. Vectura's groundbreaking research and development efforts have led to the creation of numerous cutting-edge products aimed at addressing various respiratory conditions. Additionally, Vectura has formed strategic partnerships and collaborations with leading pharmaceutical companies, further extending its global reach. With such notable achievements, Vectura Group PLC continues to solidify its position as a trailblazing force in the pharmaceutical and stock market sectors.

Vectura Group PLC, founded in 1997, is a leading pharmaceutical company specializing in the development and commercialization of inhalation therapies. With headquarters in Chippenham, UK, Vectura has a rich history of innovation and collaboration in the respiratory field. The company has successfully partnered with global pharmaceutical companies to deliver novel inhalation products, leveraging their expertise in formulation and device technology. Vectura's broad portfolio includes a range of inhalation therapies to treat diseases such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections. By continuously advancing their technology platforms and strategic partnerships, Vectura remains committed to improving patients' lives worldwide through innovative respiratory solutions.

The main competitors of Vectura Group PLC in the market include pharmaceutical companies such as GlaxoSmithKline (GSK), Novartis, AstraZeneca, and Boehringer Ingelheim.

Vectura Group PLC is primarily active in the pharmaceutical and biotechnology industries.

The business model of Vectura Group PLC revolves around developing and commercializing innovative inhaled therapies to improve the lives of patients suffering from respiratory conditions. As a leading pharmaceutical company, Vectura focuses on the development of therapeutic products for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other respiratory illnesses. By leveraging their expertise in inhalation, formulation, and device technologies, Vectura aims to provide effective and convenient treatment options to patients worldwide. With a strong emphasis on research and development, Vectura strives to continually advance their product portfolio, partnering with pharmaceutical companies to deliver cutting-edge respiratory solutions.

Det Vectura Group P/E-forhold er 20,57.

Vectura Group KUV er 4,73.

AlleAktien Kvalitetsscore for Vectura Group er 4/10.

Den forventede Vectura Group omsætning er 212,06 mio. GBP.

Den forventede Vectura Group indtjening er 48,75 mio. GBP.

Vectura Group PLC is a British provider of products and services in the field of inhalation technology. It is a publicly traded company listed on the London Stock Exchange and employs approximately 700 people worldwide. The company's core business includes the development and production of inhalation products for customers in the pharmaceutical industry, as well as research and development services. Vectura focuses on developing solutions to improve the delivery of active substances through inhalation. One of Vectura's main products is a special inhalation device called "Akita," which allows for controlled and effective administration of medication directly to the lungs. The Akita system is used by many pharmaceutical companies to develop their own inhalable medications. In addition, Vectura offers support in the form of formulation and analytics services, focusing on the development and optimization of inhalation preparations, as well as conducting tests and studies on the effectiveness and safety of these products. Other business areas of Vectura include the manufacturing of specialized inhalers for customers in the animal health sector, and the development of products for the treatment of respiratory diseases such as asthma or COPD. Overall, Vectura's business model is diverse, encompassing both product development and the provision of services in the field of inhalation technology. The company specializes in the development of advanced inhalation products that enable better effectiveness and tolerability of medications. With the increasing number of respiratory diseases worldwide, Vectura's market prospects are promising. Through close collaborations with reputable pharmaceutical companies and continuous improvements in its own technologies and products, Vectura Group PLC aims to achieve strong growth and establish itself as a leading company in the field of inhalation technology.

Vectura Group udbetaler et udbytte på 0 GBP fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Vectura Group, eller selskabet udbetaler ikke udbytte.

ISIN'en for Vectura Group er GB00BKM2MW97.

WKN for Vectura Group er A2PTCY.

Tickeren for Vectura Group er VEC.L.

I løbet af de sidste 12 måneder betalte Vectura Group en dividende på 0,06 GBP . Dette svarer til et dividendeudbytte på omkring 3,64 %. For de kommende 12 måneder vil Vectura Group sandsynligvis betale en dividende på 0 GBP.

Udbytteafkastet for Vectura Group er i øjeblikket 3,64 %.

Vectura Group betaler kvartalsvis udbytte. Dette uddeles i månederne .

Vectura Group betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 GBP. Dette svarer til et dividendeafkast på 0 %.

Vectura Group bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Vectura Group fra den 11.6.2021 på 0,19 GBP, skulle du have haft aktien i din portefølje før ex-datoen den 1.6.2021.

Udbetalingen af det sidste udbytte blev foretaget den 11.6.2021.

I løbet af 2023 udbetalte Vectura Group 0 GBP i form af dividender.

Udbytterne fra Vectura Group udbetales i GBP.